Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Clearmind Medicine Inc. has enrolled the first patients with Alcohol Use Disorder (AUD) in its ongoing clinical trial evaluating CMND-100, a proprietary non-hallucinogenic psychedelic-based treatment candidate. This milestone, achieved at Hadassah Medical Center in Israel, marks the first administration of CMND-100 to AUD patients as part of the sa…